Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
Status:
Completed
Trial end date:
2017-05-03
Target enrollment:
Participant gender:
Summary
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to
provide information on amyloid burden in subjects participating in other studies (companion
protocol) such as longitudinal studies of aging and studies of biomarkers for
neurodegenerative diseases.